China Resources Pharmaceutical Group Beheer
Beheer criteriumcontroles 3/4
China Resources Pharmaceutical Group's CEO is Xiaosong Bai, appointed in Jan 2022, has a tenure of 2.83 years. total yearly compensation is CN¥3.60M, comprised of 98.6% salary and 1.4% bonuses, including company stock and options. directly owns 0.003% of the company’s shares, worth HK$1.11M. The average tenure of the management team and the board of directors is 2.8 years and 4.1 years respectively.
Belangrijke informatie
Xiaosong Bai
Algemeen directeur
CN¥3.6m
Totale compensatie
| Percentage CEO-salaris | 98.6% |
| Dienstverband CEO | 2.8yrs |
| Eigendom CEO | 0.003% |
| Management gemiddelde ambtstermijn | 2.8yrs |
| Gemiddelde ambtstermijn bestuur | 4.1yrs |
Recente managementupdates
Recent updates
China Resources Pharmaceutical Group Limited's (HKG:3320) Shares Climb 34% But Its Business Is Yet to Catch Up
Oct 07
Here's Why China Resources Pharmaceutical Group (HKG:3320) Can Manage Its Debt Responsibly
Aug 30China Resources Pharmaceutical Group (HKG:3320) Is Increasing Its Dividend To CN¥0.1697
Jun 01Subdued Growth No Barrier To China Resources Pharmaceutical Group Limited (HKG:3320) With Shares Advancing 32%
May 13China Resources Pharmaceutical Group (HKG:3320) Will Pay A Larger Dividend Than Last Year At CN¥0.1697
Apr 28China Resources Pharmaceutical Group (HKG:3320) Is Increasing Its Dividend To CN¥0.1697
Apr 14China Resources Pharmaceutical Group's (HKG:3320) Dividend Will Be Increased To CN¥0.1697
Mar 28China Resources Pharmaceutical Group Limited's (HKG:3320) Shares May Have Run Too Fast Too Soon
Jan 28We Think China Resources Pharmaceutical Group (HKG:3320) Is Taking Some Risk With Its Debt
Dec 06Does China Resources Pharmaceutical Group (HKG:3320) Have A Healthy Balance Sheet?
Sep 07Does This Valuation Of China Resources Pharmaceutical Group Limited (HKG:3320) Imply Investors Are Overpaying?
Aug 02With EPS Growth And More, China Resources Pharmaceutical Group (HKG:3320) Makes An Interesting Case
May 26These 4 Measures Indicate That China Resources Pharmaceutical Group (HKG:3320) Is Using Debt Reasonably Well
May 05China Resources Pharmaceutical Group's (HKG:3320) Shareholders Will Receive A Bigger Dividend Than Last Year
Apr 04Is There An Opportunity With China Resources Pharmaceutical Group Limited's (HKG:3320) 24% Undervaluation?
Jan 24Is China Resources Pharmaceutical Group (HKG:3320) Using Too Much Debt?
Dec 15China Resources Pharmaceutical Group Limited's (HKG:3320) Intrinsic Value Is Potentially 97% Above Its Share Price
Oct 18China Resources Pharmaceutical Group (HKG:3320) Takes On Some Risk With Its Use Of Debt
Aug 27China Resources Pharmaceutical Group (HKG:3320) Has Announced That It Will Be Increasing Its Dividend To HK$0.15
May 29China Resources Pharmaceutical Group (HKG:3320) Is Increasing Its Dividend To HK$0.15
May 02China Resources Pharmaceutical Group's (HKG:3320) Upcoming Dividend Will Be Larger Than Last Year's
Apr 07China Resources Pharmaceutical Group (HKG:3320) Has A Somewhat Strained Balance Sheet
Mar 31Are Investors Undervaluing China Resources Pharmaceutical Group Limited (HKG:3320) By 23%?
Feb 21Here's Why China Resources Pharmaceutical Group (HKG:3320) Can Manage Its Debt Responsibly
Dec 07China Resources Pharmaceutical Group Limited (HKG:3320) Shares Could Be 32% Below Their Intrinsic Value Estimate
Nov 10These 4 Measures Indicate That China Resources Pharmaceutical Group (HKG:3320) Is Using Debt Reasonably Well
Aug 29Is China Resources Pharmaceutical Group Limited (HKG:3320) Trading At A 21% Discount?
Aug 03Is China Resources Pharmaceutical Group Limited (HKG:3320) A Good Fit For Your Dividend Portfolio?
May 03Is China Resources Pharmaceutical Group (HKG:3320) A Risky Investment?
Apr 12Is China Resources Pharmaceutical Group Limited's (HKG:3320) Recent Stock Performance Influenced By Its Fundamentals In Any Way?
Mar 17Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | CN¥4b |
| Mar 31 2024 | n/a | n/a | CN¥4b |
| Dec 31 2023 | CN¥4m | CN¥4m | CN¥4b |
| Sep 30 2023 | n/a | n/a | CN¥4b |
| Jun 30 2023 | n/a | n/a | CN¥3b |
| Mar 31 2023 | n/a | n/a | CN¥4b |
| Dec 31 2022 | CN¥2m | CN¥2m | CN¥4b |
Compensatie versus markt: Xiaosong's total compensation ($USD507.86K) is about average for companies of similar size in the Hong Kong market ($USD505.66K).
Compensatie versus inkomsten: Xiaosong's compensation has increased by more than 20% in the past year.
CEO
Xiaosong Bai (53 yo)
2.8yrs
Tenure
CN¥3,601,000
Compensatie
Mr. Xiaosong Bai serves as Non-Independent Director of China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. since March 3, 2022. He serves as Executive Director and Chief Executive Officer at China Re...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| CEO & Executive Director | 2.8yrs | CN¥3.60m | 0.0032% HK$ 1.1m | |
| VP & Executive Director | 3.2yrs | CN¥2.94m | geen gegevens | |
| CFO & Executive Director | 1.4yrs | geen gegevens | geen gegevens | |
| Chief Information Officer & VP | 10.9yrs | geen gegevens | geen gegevens | |
| Company Secretary | less than a year | geen gegevens | geen gegevens | |
| Vice President | no data | geen gegevens | geen gegevens | |
| Vice President of CR Pharma & Chairman of China Resources Boya | no data | geen gegevens | geen gegevens |
2.8yrs
Gemiddelde duur
53yo
Gemiddelde leeftijd
Ervaren management: 3320's management team is considered experienced (2.8 years average tenure).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| CEO & Executive Director | 2.8yrs | CN¥3.60m | 0.0032% HK$ 1.1m | |
| VP & Executive Director | 3.2yrs | CN¥2.94m | geen gegevens | |
| CFO & Executive Director | less than a year | geen gegevens | geen gegevens | |
| Independent Non-Executive Director | 8.4yrs | CN¥270.00k | geen gegevens | |
| Non-Executive Director | 2.8yrs | geen gegevens | geen gegevens | |
| Independent Non-Executive Director | 8.4yrs | CN¥270.00k | geen gegevens | |
| Independent Non-Executive Director | 8.4yrs | CN¥270.00k | geen gegevens | |
| Chairman of China Resources Double-Crane Pharmaceutical Co. | 5.9yrs | geen gegevens | geen gegevens | |
| Non-Executive Director | 1.8yrs | geen gegevens | geen gegevens | |
| Independent Non-Executive Director | 7.3yrs | CN¥270.00k | geen gegevens | |
| Chairman | 5.1yrs | geen gegevens | 0.0048% HK$ 1.7m | |
| Non-Executive Director | less than a year | geen gegevens | geen gegevens |
4.1yrs
Gemiddelde duur
57yo
Gemiddelde leeftijd
Ervaren bestuur: 3320's board of directors are considered experienced (4.1 years average tenure).